These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27222197)

  • 1. The evolution of prescription drug monitoring programs.
    Ashburn MA
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):852-3. PubMed ID: 27222197
    [No Abstract]   [Full Text] [Related]  

  • 2. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From Dark Dens to Suburban Townhouses: Creating a Centralized System for Prescription Opiate Monitoring to Combat the Addiction Epidemic in the United States.
    Mitchell CA
    J Leg Med; 2018; 38(1):119-162. PubMed ID: 29697320
    [No Abstract]   [Full Text] [Related]  

  • 4. Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians.
    Bao Y; Pan Y; Taylor A; Radakrishnan S; Luo F; Pincus HA; Schackman BR
    Health Aff (Millwood); 2016 Jun; 35(6):1045-51. PubMed ID: 27269021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trajectories of dispensed prescription opioids among beneficiaries enrolled in a Medicaid controlled substance "lock-in" program.
    Naumann RB; Marshall SW; Gottfredson NC; Lund JL; Ringwalt CL; Skinner AC
    Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):16-24. PubMed ID: 29700904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription Monitoring Reduces Opioid Abuse, Deaths.
    Robertson D
    J Ark Med Soc; 2017 Jan; 113(7):156-157. PubMed ID: 30085460
    [No Abstract]   [Full Text] [Related]  

  • 7. Prescription drug monitoring program utilization among 15 US opioid treatment programs.
    Matusow H; Rosenblum A; Parrino M
    J Subst Abuse Treat; 2018 Feb; 85():17-20. PubMed ID: 29291767
    [No Abstract]   [Full Text] [Related]  

  • 8. Covering the Prescription Drug Monitoring Program Gap: Using Shared Decision Making to Reduce Dental Opioid Prescriptions.
    Wang TT; Hersh EV; Panchal N
    J Oral Maxillofac Surg; 2019 Jan; 77(1):7-8. PubMed ID: 30216751
    [No Abstract]   [Full Text] [Related]  

  • 9. Surgery program directors' knowledge of opioid prescribing regulations: a survey study.
    Yorkgitis BK; Raygor D; Bryant E; Brat G; Smink DS; Crandall M
    J Surg Res; 2018 Jul; 227():194-197. PubMed ID: 29804853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing diversion of controlled substances: Translating national guidelines into practice.
    Cobaugh DJ
    Am J Health Syst Pharm; 2017 Mar; 74(5):279. PubMed ID: 28213490
    [No Abstract]   [Full Text] [Related]  

  • 11. Prescription Drug Monitoring Programs and Opioid Death Rates.
    Rudman W; Corcoran P; Elliott K
    JAMA; 2017 Nov; 318(20):2044. PubMed ID: 29183062
    [No Abstract]   [Full Text] [Related]  

  • 12. Prescription Drug Monitoring Programs and Opioid Death Rates-Reply.
    Schuchat A; Guy GP; Dowell D
    JAMA; 2017 Nov; 318(20):2045. PubMed ID: 29183067
    [No Abstract]   [Full Text] [Related]  

  • 13. Controlled substance misuse risk assessment and prescription monitoring database use by dentists.
    Hoang E; Keith DA; Kulich R
    J Am Dent Assoc; 2019 May; 150(5):383-392. PubMed ID: 31029213
    [No Abstract]   [Full Text] [Related]  

  • 14. Combating an Epidemic of Prescription Opioid Abuse.
    Pon D; Awuah K; Curi D; Okyere E; Stern CS
    J Calif Dent Assoc; 2015 Nov; 43(11):673-8. PubMed ID: 26798885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions.
    Bao Y; Wen K; Johnson P; Jeng PJ; Meisel ZF; Schackman BR
    Health Aff (Millwood); 2018 Oct; 37(10):1596-1604. PubMed ID: 30273045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the Hydrocodone Schedule Change on Opioid Prescription Patterns in South Dakota.
    Kuschel LM; Mort JM
    S D Med; 2017 Oct; 70(10):449-455. PubMed ID: 28957619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects on patient retention after opioid weaning in an internal medicine residency clinic.
    Opperman CP; Butler MM; Stroud AK; Sun MR
    J Opioid Manag; 2018; 14(2):117-123. PubMed ID: 29733097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparing a prescription drug monitoring program data set for research purposes.
    O'Kane N; Hallvik SE; Marino M; Van Otterloo J; Hildebran C; Leichtling G; Deyo RA
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):993-7. PubMed ID: 27273809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of Victoria's real time prescription monitoring system (SafeScript) on a cohort of people who inject drugs.
    Dobbin M
    Med J Aust; 2021 Mar; 214(5):234-234.e1. PubMed ID: 33598935
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of Victoria's real time prescription monitoring system (SafeScript) in a cohort of people who inject drugs.
    Fetene DM; Higgs P; Nielsen S; Djordjevic F; Dietze P
    Med J Aust; 2021 Mar; 214(5):234-234.e1. PubMed ID: 33598989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.